Viewing nowAlmantin Tablets 10 mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

MFDS item code 201706674 · Approved 2017.08.21 · Insurance code 656004700
Treatment of moderate to severe Alzheimer’s disease
This medication is used to treat moderate to severe Alzheimer's disease. It helps alleviate memory decline and cognitive impairment in patients and assists in maintaining daily living abilities. Additionally, it contributes to improving quality of life by slowing the progression of symptoms. This drug helps Alzheimer's patients lead a more stable life.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver can regularly check that the patient is taking the medicine. Diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken regardless of food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1-7) Administer 5mg once daily for 7 days. Week 2 (days 8-14) Administer 10mg once daily for 7 days. Week 3 (days 15-21) Administer 15mg once daily for 7 days. From week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for patients 65 years of age or older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated for at least 7 days after administration, the dose may be increased to 20mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication should not be administered to patients with an allergy to any components of this drug. It is safe not to use in patients with severely impaired liver function or severely reduced kidney function. Caution should be exercised when administering to patients with epilepsy or past history of seizures, or in patients who have a high risk of seizures. Avoid co-administration with other medications that have similar effects, as this may exacerbate side effects. Patients who may have changes in urine acidity due to urinary tract infections or dietary changes need careful monitoring of their condition. Use with caution in patients with heart disease or uncontrolled hypertension, as the safety of this medication has not been fully established in these populations. During treatment, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur; consult a physician if symptoms worsen. Inform healthcare providers before starting new medications, as interactions may occur. Women who are pregnant or may become pregnant should exercise caution before using this medication, and those who are nursing should ideally discontinue breastfeeding. It is recommended not to use this medication in children or adolescents under 18 years of age as safety and efficacy have not been established. In cases of overdose, central nervous system symptoms or gastrointestinal symptoms may appear, and medical attention should be sought immediately if suspected. This medication may impair responsiveness, so caution is needed while driving or operating machinery. Store out of reach of children and do not transfer to another container.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture, and keep it at room temperature between 1 and 30 degrees Celsius. Proper storage maintains the efficacy and prevents degradation of the medication.
White rectangular film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.